{
    "thread": {
        "uuid": "78f242bc37c5aaa5e3942857874be19c0fdaf258",
        "url": "https://www.canberratimes.com.au/story/8580645/new-drug-veoza-approved-to-treat-menopausal-symptoms-in-australia",
        "site_full": "www.canberratimes.com.au",
        "site": "canberratimes.com.au",
        "site_section": "https://canberratimes.com.au/news",
        "site_categories": [
            "under_construction",
            "non_standard_content",
            "top_news"
        ],
        "section_title": "News | The Canberra Times | Canberra, ACT",
        "title": "New drug VEOZA approved to treat menopausal symptoms in Australia | The Canberra Times | Canberra, ACT",
        "title_full": "New drug VEOZA approved to treat menopausal symptoms in Australia | The Canberra Times | Canberra, ACT",
        "published": "2024-04-04T13:00:00.000+03:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "AU",
        "main_image": "https://www.canberratimes.com.au/images/transform/v1/crop/frm/231014648/6d6ba6fc-7ac7-48b0-8232-7ec9192777a6.JPEG/r0_75_4032_2192_w1200_h630_fmax.jpg",
        "performance_score": 0,
        "domain_rank": 5568,
        "domain_rank_updated": "2024-04-02T13:08:08.000+03:00",
        "reach": null,
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "gplus": {
                "shares": 0
            },
            "pinterest": {
                "shares": 0
            },
            "linkedin": {
                "shares": 0
            },
            "stumbledupon": {
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "78f242bc37c5aaa5e3942857874be19c0fdaf258",
    "url": "https://www.canberratimes.com.au/story/8580645/new-drug-veoza-approved-to-treat-menopausal-symptoms-in-australia",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Emily Anderson",
    "published": "2024-04-04T13:00:00.000+03:00",
    "title": "New drug VEOZA approved to treat menopausal symptoms in Australia | The Canberra Times | Canberra, ACT",
    "text": "Now she hopes a new non-hormonal drug will help more women.\\u003cbr\\u003eAustralian doctors will be able to prescribe menopausal women the pharmaceutical drug VEOZA from April 5 to treat hot flushes and night sweats that are known as vasomotor symptoms (VMS).\\u003cbr\\u003eUp to 80 per cent of women in menopausal transition will experience VMS.\\u003cbr\\u003eFor years Ms Mesic battled with ineffective medication and experienced other symptoms including irritability, low moods, dryness, tinnitus and severe aches and pains.\\u003cbr\\u003eThere are limited treatments available for menopause with menopausal hormonal therapy (MHT) treatments the most common option.\\u003cbr\\u003eHowever, a significant proportion were unable to take menopausal hormonal therapy (MHT) due to a past history of breast cancer or other vulnerabilities including blood clotting.\\u003cbr\\u003eMs Mesic went on MHT in July 2023 and said that improvements were instant allowed her to return to full-time work.\\u003cbr\\u003eMs Mesic is hopeful the new menopause drug VEOZA might increase the options for women who can not take hormonal therapy.\\u003cbr\\u003eThe drug owned by Japanese multi-national drug company Astellas is the first of its kind to be approved in Australia.\\u003cbr\\u003eIt costs $59.99 per month in Australia and is a prescription-only drug.\\u003cbr\\u003eHead of the education sub-committee of the board of Australasian Menopause Society Dr Elina Safro welcomed the launch of VEOZA in Australia.\\u003cbr\\u003eDr Safro works as a clinician in Dubbo and has many patients who are unable to receive hormonal therapy for their menopausal symptoms.\\u003cbr\\u003eAround 385,000 Australian women aged 40-64 years of age with moderate to severe VMS were not receiving treatment.\\u003cbr\\u003eDue to cost pressures and misconceptions, some women sought off-the-shelf treatments.\\u003cbr\\u003eVEOZA is also approved in the United States, the United Kingdom and in Europe.\\u003cbr\\u003eIndividuals should speak with their doctor to discuss what treatment is right for them.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Health"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
        "persons": [
            {
                "name": "mesic",
                "sentiment": "none"
            }
        ],
        "organizations": [
            {
                "name": "canberra times",
                "sentiment": "positive"
            },
            {
                "name": "veoza",
                "sentiment": "positive"
            },
            {
                "name": "vms",
                "sentiment": "none"
            }
        ],
        "locations": [
            {
                "name": "canberra",
                "sentiment": "none"
            },
            {
                "name": "australia",
                "sentiment": "none"
            }
        ]
    },
    "rating": null,
    "crawled": "2024-04-05T00:13:18.098+03:00",
    "updated": "2024-04-05T00:13:18.098+03:00"
}